Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research report released on Sunday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 5.3 %

Lipocine stock opened at $3.35 on Friday. Lipocine has a 1-year low of $2.91 and a 1-year high of $11.79. The company has a fifty day simple moving average of $3.63 and a 200 day simple moving average of $4.50. The company has a market cap of $17.92 million, a P/E ratio of -4.41 and a beta of 1.43.

Institutional Trading of Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC grew its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 at the end of the most recent quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.